Tag: FDA
-
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Rybrevant today.…
-
FDA Approves New indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients. “Today’s…
-
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
Two different mRNA vaccines have now shown remarkable effectiveness of about 95% in preventing COVID-19 disease in adults. As the first round of vaccine recipients become eligible to receive their second dose, we want to remind the public about the importance of receiving COVID-19 vaccines according to how they’ve been authorized by the FDA…
-
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
Action Follows Thorough Evaluation of Available Safety, Effectiveness, and Manufacturing Quality Information by FDA Career Scientists, Input from Independent Experts Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The…
-
Warnings About Using a Type of Pain and Fever Medication in Second Half of Pregnancy
The U.S. Food and Drug Administration announced in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs). These changes include new labeling to explain that if women take the medications around 20 weeks or later in their pregnancy, the drugs can cause rare but serious kidney problems in the…
-
FDA Approves First Treatment for Ebola Virus
The U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients. “Today’s action demonstrates the FDA’s ongoing commitment to responding to public health threats—both domestically and abroad—on the basis of science and data,”…
-
FDA Approves Drug Combination for Treating Mesothelioma
First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for…
-
FDA Takes Actions to Help Lower U.S. Prescription Drug Prices
Final Rule, Guidance Fulfill Plan for Safe Importation of Certain Drugs Originally Intended for Foreign Markets Today, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration took actions to help provide safe, effective, and more affordable drugs to American patients as part of the Safe Importation Action Plan,…
-
FDA Announces Major Milestone in New Era of Smarter Food Safety
In a Statement From Deputy Commissioner for Food Policy and Response – Food and Drug Administration Frank Yiannas September 21, 2020: Today, I am excited to announce an important, critical step forward in the U.S. Food and Drug Administration’s efforts to bring about farm-to-table traceability in our food supply. The FDA has proposed a new…
-
FDA approves new nasal spray medication for treatment-resistant depression
The US Food and Drug Administration held a meeting on February 12, 2019 in Silver Springs, Maryland approved a new nasal spray, a medication for treatment-resistant depression.